|Other names||School sores, impetigo contagiosa|
|A case of impetigo on the chin|
|Specialty||Dermatology, Infectious disease|
|Symptoms||Yellowish skin crusts, painful|
|Complications||Cellulitis, poststreptococcal glomerulonephritis|
|Usual onset||Young children|
|Duration||Less than 3 weeks|
|Causes||Staphylococcus aureus or Streptococcus pyogenes which spreads by direct contact|
|Risk factors||Day care, crowding, poor nutrition, diabetes mellitus, contact sports, breaks in the skin|
|Prevention||Hand washing, avoiding infected people, cleaning injuries|
|Treatment||Based on symptoms|
|Medication||Antibiotics (mupirocin, fusidic acid, cefalexin)|
|Frequency||140 million (2010)|
Impetigo is a bacterial infection that involves the superficial skin. The most common presentation is yellowish crusts on the face, arms, or legs. Less commonly there may be large blisters which affect the groin or armpits. The lesions may be painful or itchy. Fever is uncommon.
It is typically due to either Staphylococcus aureus or Streptococcus pyogenes. Risk factors include attending day care, crowding, poor nutrition, diabetes mellitus, contact sports, and breaks in the skin such as from mosquito bites, eczema, scabies, or herpes. With contact it can spread around or between people. Diagnosis is typically based on the symptoms and appearance.
Prevention is by hand washing, avoiding people who are infected, and cleaning injuries. Treatment is typically with antibiotic creams such as mupirocin or fusidic acid. Antibiotics by mouth, such as cefalexin, may be used if large areas are affected. Antibiotic-resistant forms have been found.
Impetigo affected about 140 million people (2% of the world population) in 2010. It can occur at any age, but is most common in young children. In some places the condition is also known as "school sores". Without treatment people typically get better within three weeks. Recurring infections can occur due to colonization of the nose by the bacteria. Complications may include cellulitis or poststreptococcal glomerulonephritis. The name is from the Latin impetere meaning "attack".
Signs and symptoms
This most common form of impetigo, also called nonbullous impetigo, most often begins as a red sore near the nose or mouth which soon breaks, leaking pus or fluid, and forms a honey-colored scab, followed by a red mark which often heals without leaving a scar. Sores are not painful, but they may be itchy. Lymph nodes in the affected area may be swollen, but fever is rare. Touching or scratching the sores may easily spread the infection to other parts of the body.
Bullous impetigo, mainly seen in children younger than 2 years, involves painless, fluid-filled blisters, mostly on the arms, legs, and trunk, surrounded by red and itchy (but not sore) skin. The blisters may be large or small. After they break, they form yellow scabs.
Ecthyma, the nonbullous form of impetigo, produces painful fluid- or pus-filled sores with redness of skin, usually on the arms and legs, become ulcers that penetrate deeper into the dermis. After they break open, they form hard, thick, gray-yellow scabs, which sometimes leave scars. Ecthyma may be accompanied by swollen lymph nodes in the affected area.
Impetigo is primarily caused by Staphylococcus aureus, and sometimes by Streptococcus pyogenes. Both bullous and nonbullous are primarily caused by S. aureus, with Streptococcus also commonly being involved in the nonbullous form.
Impetigo is more likely to infect children ages 2–5, especially those that attend school or day care. 70% of cases are the nonbullous form and 30% are the bullous form. Impetigo occurs more frequently among people who live in warm climates.
The infection is spread by direct contact with lesions or with nasal carriers. The incubation period is 1–3 days after exposure to Streptococcus and 4–10 days for Staphylococcus. Dried streptococci in the air are not infectious to intact skin. Scratching may spread the lesions.
Impetigo is usually diagnosed based on its appearance. It generally appears as honey-colored scabs formed from dried sebum and is often found on the arms, legs, or face. If a visual diagnosis is unclear a culture may be done to test for resistant bacteria.
To prevent the spread of impetigo the skin and any open wounds should be kept clean and covered. Care should be taken to keep fluids from an infected person away from the skin of a non-infected person. Washing hands, linens, and affected areas will lower the likelihood of contact with infected fluids. Scratching can spread the sores; keeping nails short will reduce the chances of spreading. Infected people should avoid contact with others and eliminate sharing of clothing or linens. Children with impetigo can return to school 24 hours after starting antibiotic therapy as long as their draining lesions are covered.
Antibiotics, either as a cream or by mouth, are usually prescribed. Mild cases may be treated with mupirocin ointments. In 95% of cases, a single seven-day antibiotic course results in resolution in children. It has been advocated that topical antiseptics are inferior to topical antibiotics, and therefore should not be used as a replacement. However, the National Institute for Health and Care Excellence (NICE) as of February 2020 recommends a hydrogen peroxide 1% cream antiseptic rather than topical antibiotics for localised non-bullous impetigo in otherwise well individuals. This recommendation is part of an effort to reduce the overuse of antimicrobials that may contribute to the development of resistant organisms such as MRSA.
More severe cases require oral antibiotics, such as dicloxacillin, flucloxacillin, or erythromycin. Alternatively, amoxicillin combined with clavulanate potassium, cephalosporins (first-generation) and many others may also be used as an antibiotic treatment. Alternatives for people who are seriously allergic to penicillin or infections with methicillin-resistant Staphococcus aureus include doxycycline, clindamycin, and trimethoprim-sulphamethoxazole, although doxycycline should not be used in children under the age of eight years old due to the risk of drug-induced tooth discolouration. When streptococci alone are the cause, penicillin is the drug of choice. When the condition presents with ulcers, valacyclovir, an antiviral, may be given in case a viral infection is causing the ulcer.
Without treatment, individuals with impetigo typically get better within three weeks. Complications may include cellulitis or poststreptococcal glomerulonephritis. Rheumatic fever does not appear to be related.
Globally, impetigo affects more than 162 million children in low- to middle-income countries. The rates are highest in countries with low available resources and is especially prevalent in the region of Oceania. The tropical climate and high population in lower socioeconomic regions contribute to these high rates. Children under the age of 4 in the United Kingdom are 2.8% more likely than average to contract impetigo; this decreases to 1.6% for children up to 15 years old. As age increases, the rate of impetigo declines, but all ages are still susceptible.
Impetigo was originally described and differentiated by William Tilbury Fox around 1864. The word impetigo is the generic Latin word for 'skin eruption', and it stems from the verb impetere 'to attack' (as in impetus). Before the discovery of antibiotics, the disease was treated with an application of the antiseptic gentian violet, which was an effective treatment.
- "Impetigo - school sores". Bettel Health Channel. Archived from the original on 5 July 2017. Retrieved 10 May 2017.
- Ibrahim F, Khan T, Pujalte GG (December 2015). "Bacterial Skin Infections". Primary Care. 42 (4): 485–499. doi:10.1016/j.pop.2015.08.001. PMID 26612370. S2CID 29798971.
- Hartman-Adams H, Banvard C, Juckett G (August 2014). "Impetigo: diagnosis and treatment". American Family Physician. 90 (4): 229–235. PMID 25250996.
- Adams BB (2002). "Dermatologic disorders of the athlete". Sports Medicine. 32 (5): 309–321. doi:10.2165/00007256-200232050-00003. PMID 11929358. S2CID 34948265.
- Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, et al. (January 2012). "Interventions for impetigo". The Cochrane Database of Systematic Reviews. 1 (1): CD003261. doi:10.1002/14651858.CD003261.pub3. PMC 7025440. PMID 22258953.
- Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–2196. doi:10.1016/S0140-6736(12)61729-2. PMC 6350784. PMID 23245607.
- "Impetigo symptoms and treatments". www.nhsinform.scot. Retrieved 2020-05-26.
- "Impetigo and Ecthyma - Skin Disorders". Merck Manuals Consumer Version. Retrieved 2020-05-26.
- Concise English Dictionary. Wordsworth Editions Limited. 1993. p. 452. ISBN 9781840224979. Archived from the original on 2016-10-03.
- Cole C, Gazewood J (March 2007). "Diagnosis and treatment of impetigo". American Family Physician. 75 (6): 859–864. PMID 17390597. Archived from the original on 2015-04-30.
- Mayo Clinic staff (5 October 2010). "Impetigo". Mayo Clinic Health Information. Mayo Clinic. Archived from the original on 28 November 2012. Retrieved 25 August 2012.
- Kumar V, Abbas AK, Fausto N, Mitchell RN (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. p. 843. ISBN 978-1-4160-2973-1.
- Stulberg DL, Penrod MA, Blatny RA (July 2002). "Common bacterial skin infections". American Family Physician. 66 (1): 119–124. PMID 12126026. Archived from the original on 2007-09-29.
- "Impetigo (school sores)". www.health.govt.nz. Ministry of Health. Retrieved 14 September 2017.
- Tamparo C, Lewis M (2011). Diseases of the Human Body. Philadelphia, PA: F.A. Davis Company. p. 194. ISBN 9780803625051.
- "ISDH: Impetigo". state.in.us. Archived from the original on 11 December 2014. Retrieved 11 December 2014.
- "Impetigo: MedlinePlus Medical Encyclopedia". medlineplus.gov. Archived from the original on 2016-11-07.
- "Self-management - Impetigo - Mayo Clinic". www.mayoclinic.org. Archived from the original on 16 October 2016. Retrieved 7 October 2016.
- Baddour L. "Impetigo". UpToDate. Retrieved 2018-08-15.
- Fleisher GR, Ludwig S (2010-01-01). Textbook of Pediatric Emergency Medicine. Lippincott Williams & Wilkins. p. 925. ISBN 9781605471594. Archived from the original on 2017-09-08.
- "Impetigo: antimicrobial prescribing - NICE guideline [NG153]". www.nice.org.uk. Retrieved 2020-05-26.
- Mahase E (August 2019). "Doctors should treat impetigo with antiseptics not antibiotics, says NICE". BMJ. 366: l5162. doi:10.1136/bmj.l5162. PMID 31416810. S2CID 201018620.
- "Valacyclovir Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 17 March 2019.
- Bowen AC, Mahé A, Hay RJ, Andrews RM, Steer AC, Tong SY, Carapetis JR (2015). "The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma". PLOS ONE. 10 (8): e0136789. Bibcode:2015PLoSO..1036789B. doi:10.1371/journal.pone.0136789. PMC 4552802. PMID 26317533.
- Romani L, Steer AC, Whitfeld MJ, Kaldor JM (August 2015). "Prevalence of scabies and impetigo worldwide: a systematic review". The Lancet. Infectious Diseases. 15 (8): 960–967. doi:10.1016/S1473-3099(15)00132-2. PMID 26088526.
- George A, Rubin G (June 2003). "A systematic review and meta-analysis of treatments for impetigo". The British Journal of General Practice. 53 (491): 480–487. PMC 1314624. PMID 12939895.
- "Impetigo". The British Medical Journal. 1 (4185): 448. 1941. doi:10.1136/bmj.1.4185.445-a. JSTOR 20319413. S2CID 214846855.
- The Barnhart Concise Dictionary of Etymology. Harper Collins. 1995. ISBN 978-0-06-270084-1.
- MacDonald RS (October 2004). "Treatment of impetigo: paint it blue". BMJ. 329 (7472): 979. doi:10.1136/bmj.329.7472.979. PMC 524121. PMID 15499130.
- Tilbury Fox, William (1864). On impetigo contagiosa, or porrigo. England: Printed by T. Richards.